INTRODUCTION
L-Asparaginase (L-ASNase) catalyzes the hydrolysis of the non-essential amino acid L-Asn to L-Asp and ammonia. L-ASNase is widely used for the treatment of haematopoetic diseases such as acute lymphoblastic leukemia (ALL). The antineoplastic activity results from depletion of the circulating pools of L-Asn by Lasparaginase [1, 2] . Unlike normal cells, malignant cells can only synthesize L-Asn slowly and are dependent on an exogenous supply [1, 2] . In contrast, normal cells are protected from Asn starvation by their ability to produce this amino acid [3] . Thus, unlike conventional cancer therapy, L-ASNase therapy is highly selective.
The main restrictions to the use of L-ASNase as a therapeutic agent include its premature inactivation and rapid clearance, thus necessitating frequent injections to maintain therapeutic levels, and several types of side effects ranging from mild allergies and development of immune responses to anaphylactic shock, which may be life-threatening [4] [5] [6] [7] . To date, the most promising approach to extend the half-life and reduce the immunogenicity and antigenicity of therapeutic proteins is to covalently couple them to poly(ethylene glycol) (PEG) [8] [9] [10] . In this process (PEGylation), PEG is attached to the therapeutic protein by covalent linkage to residues located at the surface of the native protein [11] . PEGylation of proteins usually results in masking of some surface sites, increasing the molecular size and enhancing steric hindrance. Thus, attachment of PEG to proteins reduces their immunogenicity, improves pharmacokinetics [12, 13] , plasma half-life, and protects the proteins against proteolytic cleavage [14] [15] [16] [17] . The in vivo activity of the modified protein can sometimes be enhanced due to longer half-life in the circulation after conjugation, even though there may be some reduction in in vitro activity.
PEGylation has been extensively used to modify various proteins such as adenosine deaminase [18] , superoxide dismutase [19] , asparaginase [20] , urokinase [21] , hirudin [22] , hemoglobin [23] , interferon [24] , etc. In the USA, there are currently six polymer-modified proteins that have already been approved by the FDA and about a dozen more in various phases of clinical development [25] .
The toxicity of L-ASNase is also partially attributable to the glutaminase activity of these enzymes [26] . Thus, L-ASNases with high specificity for L-Asn and low-to-negligible activity against L-Gln are reported to be less troublesome during the course of anti-cancer therapy [27] . The interest in L-asparaginase from Erwinia Biochemical Journal Immediate Publication. Published on 21 Feb 2007 as manuscript BJ20061708 carotovora arose from the fact that it shows reduced glutaminase activity, and it is therefore believed to have fewer side effects when used in anti-cancer therapy [28] .
All asparaginases are homotetramers with 222-symmetry and a molecular mass in the range of 140-150 kDa, with a highly conserved overall fold [29] [30] [31] . They are composed of four identical subunits denoted A, B, C, and D [32] . Each monomer consists of about 330 amino acid residues that form 14 β-strands and 8 α-helices, which are arranged in two easily identifiable domains: the larger N-terminal domain and the smaller C-terminal domain. These are connected by a linker consisting of ~20 residues. Each of the four active sites is located between the N-and C-terminal domains of two adjacent monomers. Thus, the asparaginase tetramer can be treated as a dimer of dimers, as the active site is derived from subunits A and C or from subunits B and D.
For many pharmaceutical proteins, enzymatic proteolysis makes maintaining appropriate serum levels problematic. The use of L-ASNase in therapy is limited by its premature inactivation. For example, it has been reported that serum trypsin levels increase significantly 10 and 20 days after the start of ASNase therapy [33, 34] . Here we report an efficient approach for the construction of water soluble and trypsinresistant PEGylated L-ASNase from Erwinia carotovora, based on protein chemistry and protein engineering.
MATERIALS AND METHODS

MATERIALS
L-Asn and L-Gln were obtained from Serva (Heidelberg, Germany 
METHODS
Cloning, expression, and purification of EcaL-ASNase
L-asparaginase from Erwinia carotovora NCYC 1526 (EcaL-ASNase) was cloned into a T7 expression vector (pCR ® T7/CT-TOPO ® ), as described by Kotzia and Labrou [35] . The resulting expression construct pT7ASNase was used to transform competent BL21(DE3)pLysS E. coli cells, in which the synthesis of EcaL-ASNase was induced by 1 mM IPTG. The produced enzyme was purified from the other proteins using affinity chromatography on L-Asn-Sepharose CL6B column, according to Kotzia and Labrou [35] .
Kinetic analysis of mutants and PEGylated enzymes
Enzyme assays were performed at 37 °C at a Hitachi U-2000 double beam uv-vis spectrophotometer carrying a thermostated cell holder (10 mm pathlength). Activities were measured by determining the rate of ammonia formation, by coupling with glutamate dehydrogenase (GDH), according to Balcao et al. [36] . The final assay The kinetic parameters were calculated by non-linear regression analysis of experimental steady-state data. Kinetic data were analyzed using the computer program GraFit (Erithacus Software Ltd., [38] ). Kinetic experiments were repeated three times to verify the results.
CaCl 2 ) to EcaL-ASNase at a L-ASNase/trypsin ratio of 1:35 (w/w). Samples were withdrawn at selected incubation intervals and the trypsinolysis was stopped by freezing the samples with liquid nitrogen. All samples were lyophilized and then analyzed by SDS-PAGE.
Site-directed mutagenesis, expression and purification of mutants
Site-directed mutagenesis of Arg206 was carried out by overlap extension using the polymerase chain reaction (PCR) [39] . sonicated and left at 4 ºC under agitation. After 1h, cells were centrifuged at 10000g for 5 min and the supernatants were collected. Cell-free extracts of E. coli transformants showed high asparaginase activity. The collected supernatants were applied to L-Asn-Sepharose CL6B affinity column (2 ml, 1.5 x 1.5 cm I.D.)
previously equilibrated with 5 mM potassium phosphate buffer, pH 7.5 [35] . Nonadsorbed protein was washed off with 20 ml equilibration buffer. Bound L-ASNase (Arg206His or Arg206Gln) was eluted with equilibration buffer containing 10 mM L-Asn (6 ml). Collected fractions (1 ml) were assayed for L-ASNase activity and protein (A 280 or Bradford [37] ). The results from a typical purification run showed for the Arg206Gln, 75.4-fold purification with 95.3% yield, for the Arg206His mutant showed 119.7-fold purification with 96.5% yield and for the Lys30Ala mutant 110fold purification with 97% yield. [40] .
Modification of the EcaL-ASNase and mutant Arg206His with mPEG-SNHS and purification of the PEGylated enzymes
Succinylation
EcaASNase was succinylated with succinic anhydride as described in [41] with the following modifications: succinic anhydride crystals were added to 10 mM final allowed to proceed for 6h at 4 ºC, before it was stopped by the addition of 12 mM glycine, pH 9. The extent of reaction with lysyl residues was determined from titration of free amino groups with trinitrobenzene sulfonic acid [42] .
Limited proteolysis with trypsin of Arg206His and PEGylated enzymes
Agr206His, PEG-EcaL-ASNase and PEG-Arg206His, previously equilibrated in 10 mM Tris-HCl pH 7.4, were subjected to trypsin digestion. Proteolysis was carried out using L-ASNase/trypsin ratio of 1:35 (w/w). All samples were lyophilized and then analyzed by SDS-PAGE. Gels run with a Laemmli buffer system [43] . The intensities of bands were quantified with the 1D Image Analysis Software (Version 3.5, Kodak) analysis software. The intensity change versus time was fit to the first-order rate equation 1:
where I is the intensity at time t, I 0 is the intensity at t=0, and k obs is a first-order rate constant.
Thermal stability of EcaL-ASNase, Arg206His and PEGylated enzymes
Irreversible thermal inactivation of EcaL-ASNase, Arg206His and PEGylated enzymes was monitored by activity measurements. Samples of the enzymes, in 50 mM potassium phosphate buffer pH 8.5, were incubated at different temperatures (35 ºC-50 ºC) for 7.5 min. Subsequently the samples were assayed for residual activity, using the coupled enzyme assay method described above. The T m values were determined from the plots of relative inactivation (%) versus temperature (°C). T m value is the temperature at which 50% of the initial enzyme activity is lost after heat treatment.
The time course of thermal inactivation of EcaL-ASNase, Arg206His and PEGylated enzymes, in 50 mM potassium phosphate buffer pH 8.5, was studied at 37°C. The rate of inactivation was followed by periodically removing samples for assay of enzymatic 
RESULTS and DISCUSSION
Limited proteolysis of EcaL-ASNase
To obtain information about the protease-sensitive cleavage sites in EcaL-ASNase, limited proteolysis with trypsin was carried out. To follow the time course of formation and disappearance of proteolytic fragments, samples were withdrawn from the tryptic digestion mixture at intervals and subjected to SDS-PAGE for separation of the proteolytic products ( Figure 1A) . In particular, Lys53 is located at the short β-sheet formed by residues Asn51-Val57.
Arg206 is located at a flexible segment, formed by residues Asp201-Asp221, which connects the N-terminal and C-terminal domains ( Figure 1B) .
Our results thus showed that in order to engineer resistance to trypsin cleavage into EcaL-ASNase, two main amino acid targets should be considered: Lys53 and Arg206. Taking into account that Lys53 is located at a surface accessible to the solvent and that this residue can be efficiently protected through chemical modification with succinimide esters of poly(ethylene glycol), Arg206 was selected for site-directed mutagenesis.
Site-directed mutagenesis of EcaL-ASNase
On the basis of limited proteolysis and computational analysis studies, Arg206
was selected for site-directed mutagenesis. This residue was mutated to the conserved residues His and Gln, which are not recognized targets of trypsin. Kinetic analysis of the mutants was carried out to evaluate the effect of each mutation on substrate binding and catalysis, and the results are given in Table 1 . Arg206His showed differences in K m and specific activity values for L-Asn when compared to the wildtype enzyme. In particular, mutant Arg206His showed an increase in K m value of about 6.4-fold for L-Asn and a slight decrease in specific activity (~9%) compared to the wild-type enzyme. Arg206Gln gave low expression levels and worse kinetic properties compared to Arg206His (data not shown); thus, it was not considered further.
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The mutant Arg206His was subjected to limited proteolysis with trypsin, under the same conditions as used for the wild-type enzyme, in order to verify the absence of the ~25 kDa fragment resulting from trypsin digestion. SDS-PAGE analysis of the tryptic digestion mixture showed that after 90 min of incubation, no band corresponding to ~25 kDa was formed ( Figure 2 ).
PEGylation of EcaL-ASNase and the Arg206His mutant enzyme
PEGylation has become one of the most extensively used techniques, and has attracted increasing attention for enhancement of the therapeutic potential of proteinbased pharmaceuticals [18] [19] [20] [21] [22] [23] [24] [25] . Recent advances in recombinant technology and the development of functional group-selective reactive PEG derivatives have led to the creation of PEGylated proteins or mutants with markedly enhanced in vitro and in vivo characteristics and with minimal loss of bioactivity compared to their unmodified equivalents [13] .
Various factors including inherent nucleophilicity, solvation, protein conformation, and also local electronic and pK a effects determine the actual reactivity of the potential PEGylation sites [44] . The reaction chemistry and the length of PEG chains are the minimum set of variables that can determine the biological activity and stability of the modified protein [7, 13] . In the present work, the Nhydroxysuccinamide derivative of PEG (mPEG-SNHS) was employed. mPEG-SNHS allows linkage between PEG and exposed Lys residues and/or the N-terminal amino group in proteins under mild conditions of pH and temperature [45] . This approach is suitable for EcaL-ASNase because the enzyme contains twenty lysine residues in addition to the N-terminal amino acid. None of these lysine residues are located in regions of the protein that are directly involved in substrate binding and catalysis [39] .
Purified L-ASNases (wild-type and the Arg206His mutant) were subjected to Arg206His retained 82%. The tendency to lose activity can be attributed to the steric hindrance caused by the conjugation of PEG to the free amino groups on the protein surface, which prevents L-Asn from approaching the active site of the enzyme [46] .
The modification of EcaL-ASNase and Arg206His with mPEG-SNHS led to a 3.6-to 5-fold increase in K m value for L-Asn and L-Gln, respectively. The increased K m value for L-Asn, although undesirable, is still within the range of acceptability for therapeutic applications [47] . On the other hand, the increase in K m value by 5-fold (24.8 mM) for L-Gln is desirable, since the ability of therapeutic preparations of Lasparaginases to hydrolyze L-Gln has been implicated to cause several side effects [27] .
To analyze whether the effect of PEGylation on K m value (K m =0.09 ±0.03 mM for L-Asn) is the result of modification of a specific Lys residue or from the structure/chemistry of PEG we employed protein chemistry and site-directed mutagenesis studies. Complete chemical modification of EcaL-ASNase by succinic anhydrite results to a succinylated enzyme (fifteen residues succinylated per subunit) which retains unaltered its K m , in agreement with the results reported by Shifrin et al., [41] . It is apparent that extensive succinylation does not destroy enzyme function and therefore this finding indicates that none of the Lys residue is essential for catalytic activity or substrate binding.
In silico analysis of residues' accessibility in EcaL-ASNase showed that the seven, out of twenty Lys residues, that exhibit high accessible surface area are: Lys30, Lys45, Lys53, Lys145, Lys216, Lys257, Lys269. The other Lys residues are either more buried or lie at the subunit interface. These seven residues are probable the targets of chemical modification by mPEG-SNHS. Analysis of the crystal structure of the enzyme showed that none of these lysine residues are located in regions of the protein implicated in substrate binding and catalysis with the only exception that of Lys30 which lies at the flexible loop (residues 10-40, Figure 1B) near to the enzyme active site [29, 31, 35] . Site-directed mutagenesis of Lys30 to Ala gave a mutant enzyme with kinetic parameters very close to the wild-type enzyme (K m = 0.075 ± 0.03 mM for L-Asn). Therefore the results from site-directed mutagenesis and from extensive chemical modification by succinic anhydrite point to the conclusion that the influence of PEGylation on K m value is an indirect effect and may be described as originating from the overall shielding effect of the PEG chains rather than from the modification of a specific Lys residue. This conclusion is also supported by the observation that Arg206His mutant enzyme, after PEGylation, exhibits K m values or L-Asn and L-Gln comparable to that of the wild-type enzyme.
Trypsin digestion of PEGylated enzymes
To evaluate the effect of modification with PEG on the rate of trypsinolysis of PEG- contributing to the inaccessibility of the enzyme to trypsin [12, 13] .
EcaL
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Thermal stability of EcaL-ASNase, Arg206His and PEGylated enzymes
To determine the structural stability of EcaL-ASNase, Arg206His, and the PEGylated enzymes, heat inactivation studies were carried out. The enzymes were incubated at different temperatures and subsequently assayed for residual activity (Figure 4) . The corresponding T m values are listed in Table 2 . The results are summarized in Table 2 . The PEGylated enzymes showed a dramatic improvement in thermal stability at 37ºC, which is about 30.7-fold and 55.6-fold higher (for PEG-EcaL-ASNase and PEG-Arg206His, respectively) than for non-PEGylated enzymes. It is believed that PEGylation usually enhances the thermal stability of proteins by sterically blocking degradation pathways induced by hydrophobic interactions [48] , and by causing non-specific steric hindrance of the intermolecular interactions that are involved in thermal instabilities [49] .
Conclusion
A short half-life in serum is a common trait of most proteins being used or developed for therapeutic purposes. Proteolysis is being increasingly acknowledged to play a significant role in the clearance of therapeutic proteins. Thus, the design of novel proteins that are resistant to digestion, represents important strategy for the creation of next-generation therapeutic products with improved pharmacological properties. In the present study, the EcaL-ASNase was genetically modified by site-directed mutagenesis and chemically modified with mPEG-SNHS. The modified form of the mutant enzyme (PEG-Arg206His) was found to have improved proteolytic stability, good catalytic activity for L-Asn, and high structural stability. This enzyme may be 
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